Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements
The DOI matches its Crossref record.
Abstract
OBJECTIVE: This meta-analysis aimed to determine whether ambulatory blood pressure monitoring (ABPM) results from double-blind, placebo-controlled (DBPC) and prospective, randomized, open-label, blinded-endpoint (PROBE) hypertension trials are statistically comparable. METHODS: Two DBPC and three PROBE parallel-group studies were selected from an angiotensin II receptor blocker clinical programme. These were fixed-dose studies involving similar mild to moderate hypertensive patient populations. All used SpaceLabs 90207 ABPM devices, and each comprised a 4-week placebo period and a 4-8-week treatment period. Data from patients receiving telmisartan 80 mg were used to compare the results of DBPC (126 patients) and PROBE (734 patients) trials. The analysis had approximately 87% power to show equivalence between the two design types in terms of ruling out differences of >or= 3 mmHg in SBP and >or= 2 mmHg in DBP. Office blood pressure was also compared. RESULTS: The change from baseline in mean 24-h ambulatory SBP was -12.2 mmHg in DBPC trials and -12.3 mmHg in PROBE trials, a rounded difference of 0.2 mmHg [95% confidence interval (CI): -1.8, 2.1]. The change from baseline in mean 24-h ambulatory DBP was -7.7 mmHg in DBPC trials versus -7.9 mmHg in PROBE trials, a difference of 0.2 mmHg (95% CI: -1.1, 1.5). Ambulatory pulse pressure results were identical. CONCLUSIONS: Thus, changes in mean 24-h ambulatory blood pressure from the DBPC and PROBE trials in this meta-analysis are statistically equivalent in terms of ruling out a difference of >or= 3 mmHg in SBP and >or= 2 mmHg in DBP. This supports the validity of the PROBE design in assessing antihypertensive efficacy based on blinded ABPM measurements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2010) · Chronobiology International · doi:10.3109/07420528.2010.510230 · Cited by 608
“However, the PROBE design was specifically developed for the conduct of long-term morbidity and mortality trials, even when it is also frequently used today for the conduct of short-term efficacy clinical trials in patients evaluated in a blinded manner by ABPM (Smith et al., 2003).”
MethodAzizi, M., Sapoval, M., Gosse, P., Monge, M., Bobrie, G., Delsart, P., Midulla, M., Mounier-Véhier, C., Courand, P.-Y., Lantelme, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61942-5 · Cited by 519
Ibanez, B., Macaya, C., Sánchez-Brunete, V., Pizarro, G., Fernández-Friera, L., Mateos, A., Fernández-Ortiz, A., García-Ruiz, J. M., García-Álvarez, A., Iñiguez, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003653 · Cited by 394
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701127 · Cited by 203
Hermida, R. C., Ayala, D. E., Calvo, C., & López, J. E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.071 · Cited by 111
Metadata
- Authors
- Smith, D. H., Neutel, J. M., Lacourcière, Y., & Kempthorne-Rawson, J.
- Venue
- Journal of Hypertension
- Published
- 2003-07
- Volume
- 21
- Issue
- 7
- Pages
- 1291-1298
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W1965573335
- Cited by
- 112
- References
- 0
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. https://app.cochat.ai/papers/10.1097/00004872-200307000-00016
- The paper
- Smith, D. H., Neutel, J. M., Lacourcière, Y., & Kempthorne-Rawson, J. (2003). Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. Journal of Hypertension. https://doi.org/10.1097/00004872-200307000-00016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.